The amelioration of global endosomal features carried out by CoA and 4-PBA treatments led to the restoration of correct Tf trafficking, significantly decreasing cellular Tf uptake in PKAN patients, and bringing back Tf uptake to levels comparable to UT controls in both PKAN patients (Figure 4G). The gene discussed is TF; the disease is pantothenate kinase-associated neurodegeneration.